|
Laurence J. Hyman Of Counsel
Before
joining canady + lortz, Larry Hyman was a partner in the Biotechnology and Chemistry Practice Group at
Townsend and Townsend and Crew, LLP, a national, IP-focused firm (now part of Kilpatrick Townsend & Stockton LLP).
Prior to joining Townsend, Mr. Hyman practiced for more than 5 years at the National Institutes of Health's Office
of Technology Transfer, where he was the lead patent advisor for the General Medicine Workgroup. Mr. Hyman focuses his
practice on biotechnology patenting, strategic planning and counseling, technology licensing, intellectual property due diligence,
patent portfolio evaluations, and portfolio management. Mr. Hyman also advises clients on compliance with
reporting requirements for research conducted under federal funding. Mr. Hyman has represented a wide variety
of clients, including the U.S. Government, academic institutions, start-up and medium sized biotechnology and drug discovery
companies, venture capital groups, and pharmaceutical companies. He serves as a reviewer of grant applications
on therapeutics, diagnostics, and devices for the University of California, San Francisco, Clinical and Translational Science
Institute, mentors a class on IP Due Diligence for Life Sciences, and has lectured on patent law at Golden Gate University.
He also serves as a consultant on biotechnology patent matters to the Gerson Lehrman Group expert network.
Mr. Hyman was recognized as a 2011 "Top Patent Prosecutor for Pharmaceuticals/Biotechnology" by the patent
analytics website PatentBuddy.com. Mr. Hyman's patent and licensing work has
encompassed biologics (particularly antibody- and cytokine-based targeted therapeutics), protein chemistry, biochemistry,
molecular biology, RNA interference, immunology, human and animal vaccines, plant biology, agricultural methods and compositions,
transgenic plants and bacteria, biofuels, personalized medicine, enzymology, nanotechnology, stem cells, food coatings and
processing, drug administration, high throughput screening, water purification, imaging methods, radiation administration,
and microfluidic and medical devices. Education Georgetown University, M.S., Biology. Boston
University School of Law, J.D. The University of Chicago, A.B., Biological Sciences. California
New York
Massachusetts
(voluntarily on inactive status)
District of Columbia (voluntarily on inactive status)
U.S. Supreme Court
U.S. Court of Appeals for the D.C. Circuit
U.S. Court of Appeals for the Federal Circuit
Registered
patent attorney, U.S. Patent and Trademark Office
Memberships
American Bar Association,
Intellectual Property Law Section American Intellectual
Property Law Association Association of University Technology Managers State Bar of California, Intellectual Property Section
Patent Experience
The following
are U.S. patents which have issued on applications written by Laurence J. Hyman, most of which were also prosecuted by him
in whole or in part.
U.S. Patent
No. 8,263,651. Use of cis-epoxyeicosatrienoic acids and inhibitors
of soluble epoxide hydrolase to treat conditions mediated by PBR, CB2, and NK2 receptors. U.S. Patent No. 8,242,170. Use
of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy U.S. Patent No. 8,198,063. Rapid
deglycosylation of glycoproteins. U.S. Patent No. 8,124,085. Bispecific
binding agents for modulating biological activity. U.S. Patent No. 8,084,220. Methods
for detecting the presence of expanded CGG repeats in the FMR1 gene 5' untranslated region. U.S. Patent No. 8,039,593. Antibodies
and immunotoxins that target human glycoprotein NMB. U.S. Patent No. 7,982,011. Mutated
anti-CD22 antibodies and immunoconjugates. U.S. Patent No. 7,968,298. Use of
herpesviruses, herpesvirus proteins and nucleic acids encoding the proteins to inhibit CCR5-tropic HIV-1 infection and replication. U.S. Patent No. 7,951,831. Use of
inhibitors of soluble epoxide hydrolase to synergize activity of COX and 5-LOX inhibitors. U.S. Patent No. 7,927,635. Nematicides
from Juglandaceae and methods of use thereof. U.S. Patent No. 7,855,053. Methods
for detecting the presence of expanded CGG repeats in the FMR1 gene 5' untranslated region. U.S. Patent No. 7,777,019. Mutated
anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells. U.S. Patent No. 7,691,630. Compositions
for protecting plants from pathogens. U.S. Patent No. 7,666,591. Single
stranded DNA binding proteins from Archaea and uses therefor. U.S. Patent No. 7,541,040. Chimeric
molecule for the treatment of TH2-like cytokine mediated disorders. U.S. Patent No. 7,521,054. Reduction
of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the Fv to lower the isoelectric point. U.S. Patent No. 7,517,849. Inhibition
of ABC transporters by transmembrane domain analogs. U.S. Patent No. 7,470,775. Anti-CD30
stalk and anti-CD30 antibodies suitable for use in immunotoxins. U.S. Patent No. 7,404,954. Methods
of targeting agents to cells expressing the polymeric immunoglobulin receptor. U.S. Patent No. 7,399,827. Page-4,
an x-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor. U.S. Patent No. 7,368,110. Antibodies,
including Fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use. U.S. Patent No. 7,355,012. Mutated
anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells. U.S. Patent No. 7,193,054. Nanofabrication
using actin filaments. U.S. Patent No. 7,129,332. Anti-EGFRvIII
scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof. U.S. Patent No. 7,081,518. Anti-mesothelin
antibodies having high binding affinity. U.S. Patent No. 7,060,486. Inhibition
of sulfate-reducing-bacteria-mediated degradation using bacteria which secrete antimicrobials. U.S. Patent No. 7,052,911. Methods
of increasing plant yield. U.S. Patent No. 7,052,703. T-cell
receptor gamma alternate reading frame protein (TARP), and uses thereof. U.S. Patent No. 6,905,822. Methods
of diagnosing multidrug resistant tuberculosis. U.S. Patent No. 6,869,628. Methods
and formulations for providing gloss coatings to foods and for protecting nuts from rancidity. U.S. Patent No. 6,855,810. Ligands
directed to the non-secretory component, non-stalk region of plgR and methods of use thereof. U.S. Patent No. 6,852,832. Single
stranded DNA binding proteins from archaea. U.S. Patent No. 6,720,167. Insecticidal
bacteria, and methods for making and using them. U.S. Patent No. 6,696,064. Methods
of protecting vasculature from damage by diphtheria toxin-and pseudomonas toxin-based immunotoxins during therapy. U.S. Patent No. 6,630,197. Inhibition
of sulfate-reducing-bacteria-mediated degradation using bacteria which secrete antimicrobials. U.S. Patent No. 6,582,961. Methods
of protecting plants from pathogens. U.S. Patent No. 6,570,069. Nucleic
acids encoding plant inhibitors of apoptosis and transgenic cells and plants expressing them. U.S. Patent No. 6,511,824. Selective
assay for determining the identity of live microorganisms in a mixed culture. U.S. Patent No. 6,402,914. In-situ
loader for electrophoretic gels. U.S. Patent No. 6,191,103. Methods
for enhancing thrombolysis in a mammal.
|
